In contrast, ARV‐471, which is being developed in collaboration with Pfizer, focuses on the ER alpha (ERα) in ER‐positive, HER2‐negative breast cancer (Hamilton et al. 2025). This evidence concerns the gene ESR1 and breast carcinoma.